The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma

This phase 2 study evaluated the activity and safety of ibrutinib, a Bruton’s tyrosine kinase inhibitor, plus rituximab in adults with previously untreated follicular lymphoma. Patients received once‐daily ibrutinib 560 mg continuously plus once‐weekly rituximab 375 mg/m(2) for 4 weeks beginning Wee...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Fowler, Nathan H., Nastoupil, Loretta, De Vos, Sven, Knapp, Mark, Flinn, Ian W., Chen, Robert, Advani, Ranjana H., Bhatia, Sumeet, Martin, Peter, Mena, Raul, Davis, Richard Eric, Neelapu, Sattva S., Eckert, Karl, Ping, Jerry, Co, Melannie, Beaupre, Darrin M., Neuenburg, Jutta K., Palomba, M. Lia
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Haematological Malignancy ‐ Clinical
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7317728/
https://ncbi.nlm.nih.gov/pubmed/32180219
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16424
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados